Vasopressin receptor antagonism - A therapeutic option in heart failure and hypertension

Experimental Physiology

Volumn 85 S, Issue SPEC. ISS., 2000, Pages

  Burrell, Louise M ^a   Risvanis, John ^a   Johnston, Colin I ^a   Naitoh, Mareo ^a   Balding, Leanne C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; FLUID RETENTION; HEART FAILURE; HYPERPLASIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MITOGENESIS; NONHUMAN; PARACRINE SIGNALING; RAT; REVIEW; VASOCONSTRICTION; VASOPRESSIN RELEASE;

EID: 0034069082     PISSN: 09580670     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-445x.2000.tb00031.x     Document Type: Review

References (62)

1. ABRAHAM, W. T., OREN, R. M., ROBERTSON, A. D. & SCHRIER, R. W. (1997). Effects of an oral, noneptide, selective V2 receptor AVP antagonist in human heart failure. Nephrology 3, S15.
2. ABRAHAM, W. T., SURESH, D. P., WAGONER, L. E., MCCORD, J., HAAS, G. J., RYDZINSKI, S. M., NELSON, C. & BAKKER-ARKEMA, R. G. (1999). Effects of the V1a and V2 vasopressin receptor antagonist YM087 in hyponatremic patients with chronic heart failure. Journal of Cardiac Failure 5, 56.
3. ARGENT, N. B., BURRELL, L. M., GOODSHIP, T. H., WILKINSON, R. & BAYLIS, P. H. (1991). Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney International 39, 295-300.
4. BAKRIS, G., BURSZTYN, M., GAVRAS, I., BRESNAHAN, M. & GAVRAS, H. (1997). Role of vasopressin in essential hypertension: racial differences. Journal of Hypertension 15, 545-550.
5. BICHET, D. G. (1996). Vasopressin receptors in health and disease. Kidney InternationaL 49, 1706-1711.
6. BURRELL, L. M., CHAI, S. Y. & JOHNSTON, C. I. (1996a). Tissue and cellular renin-angiotensin systems. In Handbook of Hypertension, 1st edn, ed. ZANCHETTI, A., pp. 822-841. Elsevier Science, Amsterdam.
7. BURRELL, L. M., PHILLIPS, P. A., RISVANIS, J., ALDRED, K. L., HUTCHINS, A. M. & JOHNSTON, C. I. (1995). Attenuation of genetic hypertension after short-term vasopressin VIA receptor antagonism. Hypertension 26, 828-834.
8. BURRELL, L. M., PHILLIPS, P. A., RISVANIS, J., ALDRED, K. L. & JOHNSTON, C. I. (1996b). Beneficial effects of vasopressin V2/V1 receptor blockade in myocardial infarction. Journal of Hypertension 14, S158.
9. BURRELL, L. M., PHILLIPS, P. A., RISVANIS, J., CHAN, R. K., ALDRED, K. L. & JOHNSTON, C. I. (1998). Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. American Journal of Physiology 44, H176-182.
10. BURRELL, L. M., PHILLIPS, P. A., ROLLS, K. A., BUXTON, B. F., JOHNSTON, C. I. & LIU, J. J. (1994a). Vascular responses to vasopressin antagonists in man and rat. Clinical Science 87, 389-395.
11. BURRELL, L. M., PHILLIPS, P. A., STEPHENSON, J., RISVANIS, J., HUTCHINS, A. M. & JOHNSTON, C. I. (1993). Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat. Journal of Endocrinology 138, 259-266.
12. BURRELL, L. M., PHILLIPS, P. A., STEPHENSON, J. M., RISVANIS, J. & JOHNSTON, C. I. (1994B). Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260). Blood Pressure 3, 137-141.
13. BURRELL, L. M., PHILLIPS, P. A., STEPHENSON, J. M., RISVANIS, J., ROLLS, K. A. & JOHNSTON, C. I. (1994c). Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 23, 737-743.
14. BURRELL, L. M., RISVANIS, J., PHILLIPS, P. A., NAITOH, M. & JOHNSTON, C. I. (1997). Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension. Clinical and Experimental Hypertension 19, 981-991.
15. CLEMENTS, J. A. & FUNDER, J. W. (1986). Arginine vasopressin (AVP) and AVP-like immunoreactivity in peripheral tissues. Endocrine Reviews 7, 449-460.
16. CODY, R. J. (1993). Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. Journal of the American College of Cardiology 22, 165a-171a.
17. CREAGER, M. A., FAXON, D. P., CUTLER, S. S., KOHLMANN, O., RYAN, T. J. & GAVRAS, H. (1986). Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. Journal of the American College of Cardiology 7, 758-765.
18. DE PAULA, R. B., PLAVNIK, F. L., RODRIGUES, C. I. S., NEVES, F. D. R., KOHLMANN, O., RIBEIRO, A. B., GAVRAS, I. & GAVRAS, H. (1993). Contribution of vasopressin to orthostatic blood pressure maintenance in essential hypertension. American Journal of Hypertension 6, 794-798.
19. FUJISAWA, G., ISHIKAWA, S., TSUBOI, Y., OKADA, K. & SAITO, T. (1993). Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney International 44, 19-23.
20. FURUKAWA, Y., TAKAYAMA, S., REN, L. M., SAWAKI, S., INOUE, Y. & CHIBA, S. (1992). Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations. Journal of Pharmacology and Experimental Therapeutics 263, 627-631.
21. GAVRAS, H. (1990). Pressor systems in hypertension and congestive heart failure. Role of vasopressin. Hypertension 16, 587-593.
22. GAVRAS, H. & GAVRAS, I. (1989). Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. Journal of Hypertension 7, 601-606.
23. GOLDSMITH, S. R., FRANCIS, G. S., COWLEY, A. W. JR, GOLDENBERG, I. F. & COHN, J. N. (1986). Hemodynamic effects of infused arginine vasopressin in congestive heart failure. Journal of the American College of Cardiology 8, 779-783.
24. GOLDSMITH, S. R., FRANCIS, G. S., COWLEY, A. W. JR, LEVINE, T. B. & COHN, J. N. (1983). Increased plasma arginine vasopressin levels in patients with congestive heart failure. Journal of the American College of Cardiology 1, 1385-1390.
25. HUPF, H., GRIMM, D., RIEGGER, G. A. J. & SCHUNKERT, H. (1999). Evidence for a vasopressin system in the rat heart. Circulation Research 84, 365-370.
26. HUTCHINS, A. M., PHILLIPS, P. A., VENTER, D. J., BURRELL, L. M. & JOHNSTON, C. I. (1995). Molecular cloning and sequencing of the gene encoding a sheep arginine vasopressin type 1a receptor. Biochimica et Biophysica Acta 1263, 266-270.
27. JOHNSTON, C. I. (1985). Vasopressin in circulatory control and hypertension. Journal of Hypertension 3, 557-569.
28. JOHNSTON, C. I., NAITOH, M., RISVANIS, J., FARINA, N. & BURRELL, L. M. (1998). New hormonal blockade strategies in cardiovascular disease. Scandinavian Cardiovascular Journal 32, 61-66.
29. KINTER, L., CALTABIANO, S. & HOFFMAN, W. (1993). Anomalous antidiuretic activity of antidiuretic hormone antagonists. Biochemical Pharmacology 45, 1731-1737.
30. LEE, W. H. & PACKER, M. (1986). Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73, 257-267.
31. LIM, A. T., LOLAIT, S. J., BARLOW, J. W., AUTELITANO, D. J., TOH, B. H., BOUBLIK, J., ABRAHAM, J., JOHNSTON, C. I. & FUNDER, J. W. (1984). Immunoreactive arginine-vasopressin in Brattleboro rat ovary. Nature 310, 61-64.
32. MARTIN, P. Y. & SCHRIER, R. W. (1997). Sodium and water retention in heart failure: pathogenesis and treatment. Kidney International 59 (suppl.). S57-S61.
33. MULINARI, R. A., GAVRAS, I., WANG, Y. X., FRANCO, R. & GAVRAS, H. (1990). Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation 81, 308-311.
34. MURPHY, D., FUNKHOUSER, J., ANG, H. L., FOO, N. C. & CARTER, D. (1993). Extrahypothalamic expression of the vasopressin and oxytocin genes. Annals of the New York Academy of Sciences 689, 91-106.
35. NAITOH, M., BURRELL, L. M., RISVANIS, J., ALDRED, K. A., JOHNSTON, C. I. & PHILLIPS, P. A. (1997). Modulation of genetic hypertension by short term AVP V1a or V2 receptor antagonism in young spontaneously hypertensive rats. American Journal of Physiology 272, F229-234.
36. NAITOH, M., POWER, J., PHILLIPS, P. A., RISVANIS, J., JOHNSTON, C. I. & BURRELL, L. M. (1998). Effects of chronic AVP V2R blockade in congestive heart failure in sheep. Comparison with chronic ACE inhibition. Advances in Experimental Medicine and Biology 449, 445-446.
37. NAITOH, M., SUZUKI, H., MURAKAMI, M., MATSUMOTO, A., ARAKAWA, K., ICHIHARA, A., NAKAMOTO, H., OKA, K., YAMAMURA, Y. & SARUTA, T. (1994). Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. American Journal of Physiology 267, H2245-2254.
38. NAITOH, M., SUZUKI, H., MURAKAMI, M., MATSUMOTO, A., ICHIHARA, A., NAKAMOTO, H., YAMAMURA, Y. & SARUTA, T. (1993). Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs. American Journal of Physiology 265, R934-942.
39. NICOD, P., WAEBER, B., BUSSIEN, J. P., GOY, J. J., TURINI, G., NUSSBERGER, J., HOFBAUER, K. G. & BRUNNER, H. R. (1985). Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. American Journal of Cardiology 55, 1043-1047.
40. NISHIKIMI, T., KAWANO, Y., SAITO, Y. & MATSUOKA, H. (1996). Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. Journal of Cardiovascular Pharmacology 27, 275-282.
41. OHNISHI, A., ORITA, Y., OKAHARA, R., FUJIHARA, H., INOUE, T., YAMAMURA, Y., YABUUCHI, Y. & TANAKA, T. (1993). Potent aquaretic agent - a novel nonpeptide selective vasopressin-2 antagonist (OPC-31260) in men. Journal of Clinical Investigation 92, 2653-2659.
42. OHNISHI, A., ORITA, Y., TAKAGI, N., FUJITA, T., TOYOKI, T., IHARA, Y., YAMAMURA, Y, INOUE, T. & TANAKA, T. (1995). Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. Journal of Pharmacology and Experimental Therapeutics 272, 546-551.
43. OS, I., KJELDSEN, S. E., SKJOTO, J., WESTHEIM, A., LANDE, K., AAKESSON, I., FREDERICHSEN, P., LEREN, P., HJERMANN, I. & EIDE, I. K. (1986). Increased plasma vasopressin in low renin essential hypertension. Hypertension 8, 506-513.
44. PADFIELD, P. L., BROWN, J. J., LEVER, A. F., MORTON, J. J. & ROBERTSON, J. I. (1981). Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. New England Journal of Medicine 304, 1067-1070.
45. PFEFFER, J. M., PFEFFER, M. A. & BRAUNWALD, E. (1987). Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 75, 1149-155.
46. PFEFFER, M. A., BRAUNWALD, E., MOYE, L., BASTA, L., BROWN, E. J. J., CUDDY, T. E., DAVIS, B. R., GELTMAN, E. M., GOLDMAN, S. & FLAKER, G. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. New England Journal of Medicine 327, 669-677.
47. PHILLIPS, P. A., BURRELL, L. M., GOW, C. B., JOHNSTON, C. I., GRANT, S., RISVANIS, J. & ALDRED, K. (1995A). Vasopressin anatagonism: physiological and pharmacological roles. In Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research, 1st edn, ed. SAITO, T., KUROKAWA, K. & YOSHIDA, S., pp. 643-658. Elsevier Science, Amsterdam.
48. PHILLIPS, P. A., RISVANIS, J., HUTCHINS, A. M., BURRELL, L. M., MACGREGOR, D., GUNDLACH, A. L. & JOHNSTON, C. I. (1995b). Downregulation of vasopressin V1a receptor mRNA in diabetes mellitus in the rat. Clinical Science 88, 671-674.
49. RISVANIS, J., JOHNSTON, C. I., PHILLIPS, P. A. & BURRELL, L. M. (1998). Vasopressin V1a and V2 receptor mRNA in deoxycorticosterone acetate hypertension in the rat. Clinical Science 94, 517-523.
50. RISVANIS, J., NAITOH, M., JOHNSTON, C. I. & BURRELL, L. M. (1999). In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. European Journal of Pharmacology 381, 23-30.
51. SAMPEY, D. B., BURRELL, L. M. & WIDDOP, R. E. (1999). Vasopressin V-2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. American Journal of Physiology 45, R872-879.
52. SERRADEIL LE GAL, C., LACOUR, C., VALETTE, G., GARCIA, G., FOULON, L., GALINDO, G., BANKIR, L., POUZET, B., GUILLON, G., BARBERIS, C., CHICOT, D., JARD, S., VILAIN, P., GARCIA, C., MARTY, E., RAUFASTE, D., BROSSARD, G., NISATO, D., MAFFRAND, J. P. & LEFUR, G. (1996). Characterization of SR 121463a, a highly potent and selective, orally active vasopressin V2 receptor antagonist. Journal of Clinical Investigation 98, 2729-2738.
53. SHIMIZU, K. (1995). Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydopenic humans. Kidney International 48, 220-226.
54. SIMON, J. & KASSON, B. G. (1995). Identification of vasopressin mRNA in rat aorta. Hypertension 25, 1030-1033.
55. SIMON, J. S., BRODY, M. J. & KASSON, B. G. (1992). Characterization of a vasopressin-like peptide in rat and bovine blood vessels. American Journal of Physiology 262, H799-805.
56. TAHARA, A., TOMURA, Y., WADA, K. I., KUSAYAMA, T., TSUKADA, J., TAKANASHI, M., YATSU, T., UCHIDA, W. & TANAKA, A. (1997). Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics 282, 301-308.
57. TRINDER, D., PHILLIPS, P. A., STEPHENSON, J. M., RISVANIS, J., AMINIAN, A., ADAM, W., COOPER, M. & JOHNSTON, C. I. (1994). Vasopressin V1 and V2 receptors in diabetes mellitus. American Journal of Physiology 266, E217-223.
58. TSUBOI, Y., ISHIKAWA, S., FUJISAWA, G., OKADA, K. & SAITO, T. (1994). Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney International 46, 237-244.
59. WANG, Y. X., FRANCO, R., GAVRAS, I. & GAVRAS, H. (1991). Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. Journal of Laboratory and Clinical Medicine 117, 313-318.
60. YAMAMOTO, K., IKEDA, U., OKADA, K., SAITO, T., KAWAHARA, Y., OKUDA, M., YOKOYAMA, M. & SHIMADA, K. (1997). Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. Hypertension 30, 1112-1120.
61. YAMAMURA, Y., NAKAMURA, S., ITOH, S., HIRANO, T., ONOGAWA, T., YAMASHITA, T, YAMADA, Y., TSUJIMAE, K., AOYAMA, M., KOTOSAI, K., OGAWA, H., YAMASHITA, H., KONDO, K., TOMINAGA, M., TSUJIMOTO, G. & Mori, T. (1998). OPC-41061, a highly potent human vasopressin V-2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. Journal of Pharmacology and Experimental Therapeutics 287, 860-867.
62. ZHANG, X., HENSE, H. W., RIEGGER, G. A. J. & SCHUNKERT, H. (1999). Association of arginine vasopressin and arterial blood pressure in a population-based sample. Journal of Hypertension 17, 319-324.